References in periodicals archive ?
BioWa is the exclusive worldwide licensor of the POTELLIGENT Technology for creating antibody molecules with enhanced ADCC, and COMPLEGENT Technology for that with enhanced Complement-Dependent Cytotoxicity ('CDC').
Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis, as well as through apoptosis, in which a series of molecular steps in a cell lead to its death.
Rituximab is a monoclonal antibody which binds to CD20 antigen on the surface of B lymphocytes and mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Therefore, the complement-dependent cytotoxicity (CDC) crossmatch, which employs the use of lymphocytes to detect the preformed antibodies, misses the antibodies present against the MICA antigens.
It is targeted against CD20, which leads to elimination of B-lymphocytes expressing CD20 through antibody-dependent cytotoxicity [14], complement-dependent cytotoxicity [14], and apoptosis [15].
In fact, anti-thyroid antibodies are involved in pathogenesis of autoimmune thyroiditis through complement-dependent cytotoxicity [7]; hence, their appearance may actually precede development of overt thyroid disease or deranged thyroid function tests by several years [8].
HLA typing by serology: During the last 40 years HLA typing to detect this polymorphism was undertaken by the serological method better known as the complement-dependent cytotoxicity assay (CDC).
Its mechanism of action has been proposed through various models namely antigen dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptotic cell death14.
In addition to the proapoptotic features of anti-CD20 treatment, rituximab-mediated complement-dependent cytotoxicity involves ROS production, more specifically [O.up.*-.sub.2] [73].
The main advantages of monoclonal antibodies in comparison to small-molecule drugs are longer half-life, high-affinity binding to target molecules, the possibility of the development of specific mAbs for a wide range of antigens, and the ability to use the host's immune-system effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [2,3].
A well-known standard method for research in anti-HLA antibodies consists of the reaction of complement-dependent cytotoxicity (CDC) which detects complement fixers antibodies IgM and IgG.
Full browser ?